东诚药业1月15日获融资买入1409.96万元，融资余额11.96亿元

Group 1 - The core viewpoint of the news is that Dongcheng Pharmaceutical experienced a slight decline in stock price and has significant financing activities, indicating a high level of investor interest despite a decrease in revenue and profit [1][2]. Group 2 - On January 15, Dongcheng Pharmaceutical's stock fell by 0.88%, with a trading volume of 106 million yuan. The financing buy-in amount for the day was 14.10 million yuan, while the financing repayment was 10.34 million yuan, resulting in a net financing buy-in of 3.76 million yuan. The total financing and securities balance reached 1.20 billion yuan [1]. - The financing balance of Dongcheng Pharmaceutical is 1.20 billion yuan, accounting for 9.91% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1]. - On the same day, the company repaid 6,700 shares in securities lending and sold 900 shares, with a selling amount of 13,200 yuan. The remaining securities lending volume was 28,500 shares, with a balance of 417,000 yuan, which is below the 30th percentile level over the past year, indicating low activity in this area [1]. Group 3 - As of September 30, the number of shareholders of Dongcheng Pharmaceutical was 24,600, an increase of 4.51% compared to the previous period. The average circulating shares per person decreased by 4.32% to 30,191 shares [2]. - For the period from January to September 2025, Dongcheng Pharmaceutical reported revenue of 2.04 billion yuan, a year-on-year decrease of 5.52%, and a net profit attributable to shareholders of 149 million yuan, down 10.64% year-on-year [2]. Group 4 - Since its A-share listing, Dongcheng Pharmaceutical has distributed a total of 1 billion yuan in dividends, with 293 million yuan distributed over the past three years [3]. - As of December 31, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder of Dongcheng Pharmaceutical, holding 20.28 million shares, an increase of 252,100 shares compared to the previous period [3].